Search research articles
Contact Us
Filters
Showing results (21-30 of 38) with videos related to
Page
of 4
Sort By:
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
August 27, 2020
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Cinzia Aurilia, et al.
European Journal of Neurology
|
September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
February 28, 2015
Prevalence of Patent Foramen Ovale in Ischaemic Stroke in Italy: Results of SISIFO Study
Domenico Consoli, Maurizio Paciaroni, Franco Galati, et al.
The Journal of Headache and Pain
|
November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain
|
May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
The Journal of Headache and Pain
|
March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Journal of Neurology
|
April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
August 6, 2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 38) with videos related to
Sort By:
Page
of 4
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology
|
August 27, 2020
Effectiveness, safety, and tolerability of galcanezumab in a real-life setting in patients with migraine in Italy (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Cinzia Aurilia, et al.
European Journal of Neurology
|
September 13, 2022
Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: The multicenter prospective cohort GARLIT study
Fabrizio Vernieri, Nicoletta Brunelli, Marilena Marcosano, et al.
Cerebrovascular Diseases (Basel, Switzerland)
|
February 28, 2015
Prevalence of Patent Foramen Ovale in Ischaemic Stroke in Italy: Results of SISIFO Study
Domenico Consoli, Maurizio Paciaroni, Franco Galati, et al.
The Journal of Headache and Pain
|
November 1, 2022
Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
The Journal of Headache and Pain
|
May 4, 2021
Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
Fabrizio Vernieri, Claudia Altamura, Nicoletta Brunelli, et al.
The Journal of Headache and Pain
|
March 23, 2023
Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
Piero Barbanti, Gabriella Egeo, Cinzia Aurilia, et al.
Journal of Neurology
|
April 2, 2024
Correction to: Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Journal of Neurology
|
January 17, 2024
Ultra-late response (> 24 weeks) to anti-CGRP monoclonal antibodies in migraine: a multicenter, prospective, observational study
Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, et al.
Neurology and Therapy
|
March 7, 2024
Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Neurology and Therapy
|
August 6, 2024
Correction to: Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study
Piero Barbanti, Gabriella Egeo, Stefania Proietti, et al.
Page
of 4